Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity

Citation for published version:

Digital Object Identifier (DOI):
10.1101/gad.521709

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Genes & Development

Publisher Rights Statement:
Copyright © 2009 by Cold Spring Harbor Laboratory Press

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity

Simon Wilkinson, Jim O’Prey, Michael Fricker, and Kevin M. Ryan¹

Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Glasgow G61 1BD, United Kingdom

The selective regulation of macroautophagy remains poorly defined. Here we report that PDGFR signaling is an essential selective promoter of hypoxia-induced macroautophagy. Hypoxia-induced macroautophagy in tumor cells is also HIF1α-dependent, with HIF1α integrating signals from PDGFRs and oxygen tension. Inhibition of PDGFR signaling reduces HIF1α half-life, despite buffering of steady-state protein levels by a compensatory increase in HIF1α mRNA. This markedly changes HIF1α protein pool dynamics, and consequently reduces the HIF1α transcriptome. As autocrine growth factor signaling is a hallmark of many cancers, cell-autonomous enhancement of HIF1α-mediated macroautophagy may represent a mechanism for augmenting tumor cell survival under hypoxic conditions.

Supplemental material is available at http://www.genesdev.org.

Received January 9, 2009; revised version accepted April 14, 2009.

During macroautophagy, autophagosomal vesicles (autophagosomes) transport organelles or proteins from the cytosol to the lysosome [Xie and Klionsky 2007]. Cellular signals promote the formation of autophagosomes and determine which cytosolic cargoes are sequestered. Macrouptophagy has a homeostatic role in general clearing of damaged organelles and proteins in most tissues [Mizushima et al. 2004; Haral et al. 2006; Komatsu et al. 2006]. However, in certain situations, cellular stresses induce macroautophagy as an adaptive response for the maintenance of cell viability. For example, mitophagy, the specific autophagic degradation of mitochondria, can limit apoptosis in response to cytotoxic agents [Xue et al. 2001; Collell et al. 2007] or down-regulate oxidative phosphorylation as part of the adaptation of primary cells to hypoxia [Zhang et al. 2008]. When cells are under conditions of metabolic stress, such as when extracellular nutrients are low, general macroautophagy may be induced to break down cellular proteins into catabolic and anabolic precursors, relieving energy demand and assisting cell survival [Kuma et al. 2004; Scott et al. 2004; Lum et al. 2005; Jin et al. 2007]; in the absence of macroautophagy, depletion of energy levels and necrosis or apoptosis occurs [Boy et al. 2005; Jin et al. 2007]. Although macroautophagy appears to operate broadly as a survival mechanism in cells, there is also mounting evidence that in specific circumstances elevated macroautophagy may be an integral component of cell death programs, although the mechanistic basis for the pro-death role of macroautophagy is unknown [Shimizu et al. 2004; Yu et al. 2004; Feng et al. 2005; Crighton et al. 2006].

Results and Discussion

Tumor cells encounter hypoxic conditions and become metabolically stressed within poorly vascularized regions of tumors in vivo [Degenhardt et al. 2006]. Indeed, macroautophagy co-localizes with hypoxia and promotes cell survival in these regions of tumors [Degenhardt et al. 2006]. In a human tumor cell line model, BE colorectal carcinoma, stably expressing GFP-LC3, we found that hypoxia induces macroautophagy, as assessed by accumulation of GFP-LC3 puncta, a marker for autophagosomes [Fig. 1A; Kabe et al. 2000]. Using siRNA oligonucleotides targeting the macroautophagy gene ATG5 [Crighton et al. 2006], we abrogated the autophagic response [Fig. 1B–D] and observed both a decrease in cell viability under hypoxic conditions [Fig. 1E] and a decrease in long-term viability and regrowth potential when cells were replated for outgrowth in a clonogenic survival assay post-treatment [Fig. 1F]. These data show that hypoxia-induced macroautophagy is an adaptive mechanism that maintains tumor cell viability in hypoxic environments.

In order to identify signaling mechanisms controlling hypoxia-induced macroautophagy in tumor cells, we performed an RNAi screen across the protein kinome in Drosophila S2R+ GFP-LC3 reporter cells [cell line described in Supplemental Fig. 1A,B] in order to obtain candidate kinase regulators. We identified the receptor tyrosine kinase Per as necessary for accumulation of GFP-LC3 puncta in response to hypoxia [Supplemental Fig. 1C]. There are eight sequence orthologs of Per in human cells: the VEGFR family kinases Kdr, Flt4, and Flt1, and the PDGFR family kinases PDGFRα, PDGFRβ, Flk3, FMS, and Kit [Supplemental Fig. 2A]. We next sought to determine if autocrine signaling through any of these might promote hypoxia-induced macroautophagy in tumor cells.

We tested small-molecule inhibitors of VEGFR and PDGFR family member kinase activity. With VEGFR inhibitors we found no effect [data not shown], but with an inhibitor targeting the PDGFR family [PDGFR-II], we observed diminution of the accumulation of GFP-LC3 puncta in BE cells in response to hypoxia [Fig. 2A]. This effect was specific to hypoxia, as the effect of glucose or amino acid starvation in inducing accumulation of GFP-LC3 puncta was unperturbed [Fig. 2A]. The endogenous LC3-II to LC3-I ratio, another marker of autophagosome accumulation, was also increased by hypoxia, but was diminished by PDGFR-I, further confirming the conclusions from the puncta analysis [Fig. 2B]. These experiments were performed under serum-free conditions. Nevertheless, activity of PDGFRβ, the main documented activity, depletion of energy levels and necrosis or apoptosis occurs [Boy et al. 2005; Jin et al. 2007]. Although macroautophagy appears to operate broadly as a survival mechanism in cells, there is also mounting evidence that in specific circumstances elevated macroautophagy may be an integral component of cell death programs, although the mechanistic basis for the pro-death role of macroautophagy is unknown [Shimizu et al. 2004; Yu et al. 2004; Feng et al. 2005; Crighton et al. 2006].

During macroautophagy, autophagosomal vesicles (autophagosomes) transport organelles or proteins from the cytosol to the lysosome [Xie and Klionsky 2007]. Cellular signals promote the formation of autophagosomes and determine which cytosolic cargoes are sequestered. Macroautophagy has a homeostatic role in general clearing of damaged organelles and proteins in most tissues [Mizushima et al. 2004; Haral et al. 2006; Komatsu et al. 2006]. However, in certain situations, cellular stresses induce macroautophagy as an adaptive response for the maintenance of cell viability. For example, mitophagy, the specific autophagic degradation of mitochondria, can limit apoptosis in response to cytotoxic agents [Xue et al. 2001; Collell et al. 2007] or down-regulate oxidative phosphorylation as part of the adaptation of primary cells to hypoxia [Zhang et al. 2008]. When cells are under conditions of metabolic stress, such as when extracellular nutrients are low, general macroautophagy may be induced to break down cellular proteins into catabolic and anabolic precursors, relieving energy demand and assisting cell survival [Kuma et al. 2004; Scott et al. 2004; Lum et al. 2005; Jin et al. 2007]; in the absence of macroautophagy, depletion of energy levels and necrosis or apoptosis occurs [Boy et al. 2005; Jin et al. 2007]. Although macroautophagy appears to operate broadly as a survival mechanism in cells, there is also mounting evidence that in specific circumstances elevated macroautophagy may be an integral component of cell death programs, although the mechanistic basis for the pro-death role of macroautophagy is unknown [Shimizu et al. 2004; Yu et al. 2004; Feng et al. 2005; Crighton et al. 2006].

Results and Discussion

Tumor cells encounter hypoxic conditions and become metabolically stressed within poorly vascularized regions of tumors in vivo [Degenhardt et al. 2006]. Indeed, macroautophagy co-localizes with hypoxia and promotes cell survival in these regions of tumors [Degenhardt et al. 2006]. In a human tumor cell line model, BE colorectal carcinoma, stably expressing GFP-LC3, we found that hypoxia induces macroautophagy, as assessed by accumulation of GFP-LC3 puncta, a marker for autophagosomes [Fig. 1A; Kabe et al. 2000]. Using siRNA oligonucleotides targeting the macroautophagy gene ATG5 [Crighton et al. 2006], we abrogated the autophagic response [Fig. 1B–D] and observed both a decrease in cell viability under hypoxic conditions [Fig. 1E] and a decrease in long-term viability and regrowth potential when cells were replated for outgrowth in a clonogenic survival assay post-treatment [Fig. 1F]. These data show that hypoxia-induced macroautophagy is an adaptive mechanism that maintains tumor cell viability in hypoxic environments.

In order to identify signaling mechanisms controlling hypoxia-induced macroautophagy in tumor cells, we performed an RNAi screen across the protein kinome in Drosophila S2R+ GFP-LC3 reporter cells [cell line described in Supplemental Fig. 1A,B] in order to obtain candidate kinase regulators. We identified the receptor tyrosine kinase Per as necessary for accumulation of GFP-LC3 puncta in response to hypoxia [Supplemental Fig. 1C]. There are eight sequence orthologs of Per in human cells: the VEGFR family kinases Kdr, Flt4, and Flt1, and the PDGFR family kinases PDGFRα, PDGFRβ, Flk3, FMS, and Kit [Supplemental Fig. 2A]. We next sought to determine if autocrine signaling through any of these might promote hypoxia-induced macroautophagy in tumor cells.

We tested small-molecule inhibitors of VEGFR and PDGFR family member kinase activity. With VEGFR inhibitors we found no effect [data not shown], but with an inhibitor targeting the PDGFR family [PDGFR-II], we observed diminution of the accumulation of GFP-LC3 puncta in BE cells in response to hypoxia [Fig. 2A]. This effect was specific to hypoxia, as the effect of glucose or amino acid starvation in inducing accumulation of GFP-LC3 puncta was unperturbed [Fig. 2A]. The endogenous LC3-II to LC3-I ratio, another marker of autophagosome accumulation, was also increased by hypoxia, but was diminished by PDGFR-I, further confirming the conclusions from the puncta analysis [Fig. 2B]. These experiments were performed under serum-free conditions. Nevertheless, activity of PDGFRβ, the main documented...
Figure 1. Hypoxia-induced autophagy promotes cell viability in tumor cells. BE GFP-LC3 cells (3 × 10⁶) were plated overnight in six-well dishes and cultured for 8 h in normoxic conditions (21% O₂) or hypoxic conditions (1% O₂), and then fixed for fluorescence microscopic imaging of GFP-LC3 (bar, 50 μm) [A], or transfected with siRNA oligonucleotides NTC1, NTC2, ATG5 si1, or ATG5 si2 [B–F]. Forty-eight hours later, cells were immunoblotted for indicated proteins [B] or kept in normoxic conditions (21% O₂) or exposed to hypoxic conditions (0.5% O₂) [C]. Autophagy was assessed by COX-IV levels) were not targeted for degradation.

Figure 2. PDGFR family signaling promotes hypoxia-induced autophagy of cytotoxic protein. [A] BE GFP-LC3 cells at confluence were cultured in serum-free medium (SFM) (21% O₂) or EBSS (no amino acids [no a.a.] or glucose-free medium [no glucose], all at 21% O₂, or in SFM at 1% O₂, or in SFM at 1% O₂ plus DMSO vehicle or PDGFR-I (5 μM) for 8 h, whereupon cells were fixed and analyzed for GFP-LC3 puncta by fluorescence microscopy [C,D] (C contains representative images [bar, 25 μm]; D shows analysis of number of cells containing GFP-LC3 puncta [n = 3 ± SEM; *** P < 0.005 vs. either NTC]) or lysed and stained with propidium iodide for flow cytometric analysis of dead cell number [n = 3 ± SEM; * P < 0.05 vs. either NTC] or re-plated for assessment of colony formation potential upon re-exposure to normoxic conditions [n = 6 ± SD; # not significant; *** P < 0.005 vs. cells not exposed to hypoxic stress] [F].

Target of PDGFR-I that is expressed in BE cells [Supplemental Fig. 2B], was constitutively observed in both normoxic and hypoxic conditions and, as expected, this was abrogated by inhibitor treatment (Fig. 2C). These data suggest a constitutive autocrine signaling loop through PDGFRβ that is permissive for hypoxia-induced macroautophagy. Confirming this, inhibition of PDGFRβ by siRNA transfection also reduced the number of GFP-LC3 puncta seen under hypoxic conditions [Fig. 2D]. Of the other PDGFR family members, FMS was also detectable in the cells, albeit in our hands only by semiquantitative PCR [Supplemental Fig. 2B], not at the protein level. Although not documented previously, we observed that PDGFR-I could inhibit FMS kinase activity, at least in vitro [Supplemental Fig. 2C]. We therefore tested whether FMS inhibition by RNAi also reduced autophagy under hypoxic conditions, and found that this was the case (Fig. 2E). PDGFR-II, a second, chemically unrelated inhibitor of PDGFRβ, and FMS [Supplemental Fig. 2C] also decreased autophagosome levels [Supplemental Fig. 2D]. RNAi against Flt1 and Kdr, the two VEGFR family isoforms we could detect expression of in this cell line, did not inhibit autophagy [Supplemental Fig. 2E–G]. Taken together, these data show that autocrine PDGFRβ and FMS signaling permits hypoxia-induced macroautophagy in a tumor cell line. Consistent with this, we observed that these cells secrete the PDGFRβ and FMS ligands PDGF and CSF-1 [Supplemental Fig. 2H] and that addition of exogenous PDGF can modestly promote hypoxia-induced autophagy [Supplemental Fig. 2I].

Further measures of hypoxia-induced autophagy in BE cells demonstrated that, in contrast to the effect of hypoxia-induced macroautophagy in mouse embryonic fibroblasts (MEFs) [Zhang et al. 2008], mitochondria (as assessed by COX-IV levels) were not targeted for degra-
dation, while the cytosolic macroautophagy target protein p62 was degraded. We observed specific down-regulation of p62, dependent on PDGFR signaling (Fig. 2F), via a lysosomal degradation pathway inhibitable by the protease inhibitors E64d and pepstatin A (Fig. 2G). In MEFs, hypoxia-induced mitophagy is required to down-regulate oxidative phosphorylation to prevent reactive oxygen species accumulation (Zhang et al. 2008). Indeed, analysis of longer time courses of hypoxia demonstrate a markedly greater down-regulation of mitochondrial antigens [COX-IV and TOM-20] in primary MEFs as compared with BE tumor cells [Fig. 2H; quantification in Supplemental Fig. 2J]. In these tumor cells and other tumor cell lines we found to exhibit PDGFR-dependent hypoxia-induced macroautophagy [Supplemental Fig. 2K], the prosurvival role of macroautophagy in response to hypoxic stress thus may not be related to mitochondrial down-regulation but to cytosolic protein degradation instead. Analysis of canonical signaling pathways downstream from PDGFR family members in BE cells demonstrated that these were unperturbed by PDGFR-I, suggesting that PDGFR is signaling to hypoxia-induced autophagy through a non-canonical mechanism [Supplemental Fig. 2L].

Signaling responses to hypoxia fall into two main categories: HIF-dependent and HIF-independent [Pouyssegur et al. 2006]. HIF1α and HIF2α are transcription factor subunits, the stability of which increase with lower oxygen, allowing their accumulation and dimerization with HIF1β/ARNT to form a functional transcription factor [Pouyssegur et al. 2006]. Reprogramming of cellular metabolism by HIF1α up-regulated genes, such as the increase in anaerobic glycolysis by glycolytic enzymes and lactate dehydrogenase, is important for cellular fitness under hypoxia [Pouyssegur et al. 2006]. We observed that HIF1α was stabilized specifically by hypoxia in contrast to other macroautophagy-inducing stimuli [Supplemental Fig. 3A]. RNAi against ARNT resulted in effective silencing [Fig. 3A] and inhibited hypoxia-induced autophagosome accumulation [Fig. 3B]. This demonstrated a transcriptionally mediated macroautophagic response to hypoxia. Further RNAi experiments showed that macroautophagy required, specifically, HIF1α activity [Fig. 3C,D]. It is also evident that the low levels of signaling through the hypoxia response pathway under normoxia are sufficient to sponsor some HIF1α accumulation [Supplemental Fig. 3A] and autophagy induction [Supplemental Fig. 3B] in these cells, consistent with the observation of a modest inhibition of normoxic autophagy by inhibition of PDGFR family members [Fig. 2A,D,E]. BNIP3 and BNIP3L are HIF1α target genes that have been shown to mediate macroautophagy under hypoxia in MEFs or during erythrocyte maturation in vivo, respectively [Tracy et al. 2007; Sandoval et al. 2008; Zhang et al. 2008]. Where this macroautophagy has been characterized, it has been shown to be mitophagic in nature [Sandoval et al. 2008; Zhang et al. 2008]. BNIP3 and BNIP3L are regulated in response to hypoxia-mediated HIF1α activation in BE cells, ARNT siRNA transfection greatly reduced the expression levels of both genes. However, direct BNIP3 and/or BNIP3L silencing did not inhibit hypoxia-induced macroautophagy [Fig. 3E,F]. Taken together, these data suggest that the hypoxia-mediated macroautophagy seen in tumor cells is dependent on HIF1α activity. However, the PDGFR-mediated hypoxic macroautophagy here is independent of BNIP3 and BNIP3L function, consistent with the lack of a mitophagic component to this autophagy.

We next wished to determine the point at which PDGFR signaling converged with hypoxia signaling to mediate macroautophagy. Gene expression profiling revealed that PDGFR family inhibition affects HIF1α activity, as read out in the transcriptional response to hypoxia [Fig. 4A]. Microarray analysis defined 281 signals up-regulated by hypoxia. These signals were then compared against those from hypoxic cells with either HIF1α silencing or PDGFR-I treatment. On this basis, genes were assigned as less up-regulated by hypoxia under these inhibitory treatment conditions [Fig. 4A, green], further up-regulated, or unaffected [Fig. 4A, red or black, respectively, complete listing in Supplemental Fig. 4, Supplemental Table 1]. Most genes required HIF1α for up-regulation, but only a proportion of these HIF1α targets also required PDGFR family activity. Thus, HIF1α target genes are divisible into two groups: a set requiring...
As the data indicated that autocrine PDGFR signaling affects HIF1α function at some target promoters, we now wished to determine the mechanism of this inhibition. First, minimal hypoxia response element (HRE) reporter assays using a sensitive HIF-binding site from phosphoglycerate kinase (PGK), a Group I gene, revealed a decrease in hypoxic HIF-binding activity in the absence of PDGFR signaling (Fig. 5A). This indicated that the activity of the HIF1α transcriptional complex itself, involved in activating the core elements of target promoters, was perturbed. We decided to examine HIF1α behavior more closely. At steady-state, post-hypoxic induction of macroautophagy, we found an approximately equal amount of HIF1α present in control cells and cells treated with PDGFR inhibitor, and HIF1α was localized to the nuclear compartment—to which shuttling is...
required to effect transactivation—in both instances [Fig. 5B]. However, a time course of the events immediately following exposure of cells to hypoxia demonstrated that cells with inhibited PDGFR signaling exhibit a retarded accumulation of HIF1α protein only at early time points [Fig. 5C] due to enhanced proteasomal degradation, as shown by treatment with MG-132 proteasome inhibitor (Fig. 5D). However, even after several hours, when steady-state levels of HIF1α protein in cells lacking PDGFR signaling have recovered to those seen in uncompromised cells, the degradation rate of HIF1α is still markedly enhanced, as demonstrated by cycloheximide chase experiments [Fig. 5E,F]. However, the steady-state levels of HIF1α are buffered by a compensatory increase in HIF1α mRNA in the absence of PDGFR signaling, due to the abrogation of a negative feedback loop that operates to repress HIF1α mRNA under control hypoxic conditions [Fig. 5G]. Taken together, these data suggest that a more dynamic and transient pool of HIF1α protein in the absence of PDGFR signaling, being turned over faster due to balanced increases in both synthesis and degradation, has less capacity to promote transcription from HRE-containing target genes [for model, see Supplemental Fig. 6].

Macroautophagy is regulated downstream from diverse stress signals through different signaling pathways. Here we demonstrated PDGFR-mediated regulation of a hypoxia HIF1α-driven mechanism for induction of macroautophagy. It is worth noting, however, that in extreme situations, such as anoxia (<0.1% O2), HIF-independent, and presumably PDGFR-independent, mechanisms have been suggested to play a dominant role in regulating macroautophagy [Papandreou et al. 2008]. Interestingly, it has been shown previously that IL-3 promotes nutrient uptake, presumably by binding to its cognate growth factor receptor, and deprivation of this signal causes a starvation response and induction of autophagic survival [Lum et al. 2005]. Here we described a different paradigm for growth factor receptor signaling in the regulation of macroautophagy, where signaling facilitates the maximum cellular response to a cellular stress, in this instance hypoxia. We propose that autocrine PDGFR signaling allows tumor cells to autonomously maintain a level of HIF1α activity at a given oxygen tension and HIF1α protein level that is greater than it would be without this signaling. This is attained by increasing the half-life of HIF1α, which is prevented from causing runaway accumulation of HIF1α protein by negative feedback on HIF1α message levels. The consequence of the presence of this less dynamic and transient pool of HIF1α protein is to increase the number of phenotypic changes promoted by HIF1α at a given oxygen tension, and thus the number of strategies available to the tumor cell to adapt to low oxygen and the consequent metabolic stress. One such change is the induction of macroautophagy involving cytosolic protein and p62 degradation under hypoxia, distinct from the mitophagy seen in MEFs that acts to down-regulate oxidative phosphorylation [Zhang et al. 2008]. Macroautophagy maintains cell viability in the face of metabolic stress: The autocrine signaling of PDGFR, thus gives an obvious advantage to tumor cells by enabling survival in a hypoxic microenvironment during tumorigenesis.

In conclusion, identifying signaling mechanisms by which tumor cells promote macroautophagic responses to metabolic stresses, such as PDGFR signaling in response to hypoxia, will provide new targets for selective therapeutic targeting of tumor cell viability.

Materials and methods

Cell lines and reagents

BE, A431, and HCT116 cells expressing ectopic retrovirus receptor (a gift from Dan Croft) stably infected with pBabe-Puro EGFP-LC3 retrovirus ("GFP-LC3" lines), and primary MEF cells were cultured in DMEM (Gibco) supplemented with 10% FBS (HyClone). Drosophila melanogaster S2R+ GFP-LC3 cells were derived from S2R+ cells stably transfected with pAc5.1 [Invitrogen] engineered to express EGFP-Drosophila Atg8a and cultured at room temperature and atmosphere oxygen in Schneider's Drosophila medium. All mammalian cell lines were cultured in 21% O2/5% CO2 or, in the case of diminished O2, in an InVivo 500 hypoxia workstation at 5% CO2, MG132, E64d, pepstatin A, PDGFR-I (alias PDGF Receptor Tyrosine Kinase Inhibitor III), and PDGFR-II (alias PDGF Receptor Tyrosine Kinase Inhibitor II) inhibitors were obtained from Calbiochem. Bafilomycin and cycloheximide were from Sigma. Recombinant PDGF-AB was from R&D Systems, and recombinant FMS was from Cell Signaling Technology (CSFIR [K539-C972]). ELISAs were performed with Quantikine immunoassay kits for human PDGF-AB and M-CSF from R&D Systems.

Microscopy

GFP-LC3 cells were grown on glass and fixed in 4% paraformaldehyde before mounting using DAKO mountant [DAKO Cytomation]. Confocal images were obtained as Z-stacks using a Leica SP2 confocal. Cells were scored blindly for presence of GFP-LC3 puncta in multiple confocal images (>10 per condition, >200 cells) obtained using a 100× objective lens on an Axioskop 50 microscope (Zeiss). Automatic exposure times minimized differences in brightness between images due to heterogeneous expression among cells.

Acknowledgments

Thanks to Greg Findlay and Richard Lamb for generous gifts of reagents. Thanks to Yvonne Hey for microarray handling, and Keith Vass for microarray data analysis. Thanks to Dan Croft, Gareth Inman, and Dan Tennant for advice and comments. Work in the Tumour Cell Death Laboratory is supported by Cancer Research UK.

References


